Evidence map›Paper›PMID 26845514›Full record

ReviewACS chemical biology2016

Therapeutics Targeting Protein Acetylation Perturb Latency of Human Viruses.

Ryan J Conrad, Melanie Ott

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in ACS chemical biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Ryan J ConradGladstone Institute of Virology and Immunology , San Francisco, California 94158, United States.
Melanie OttGladstone Institute of Virology and Immunology , San Francisco, California 94158, United States.
Gladstone Institutes · USUniversity of California, San Francisco · US

Funding

Using NK Cells to eliminate the latent HIV reservoirU19AI096113 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LUCIW, PAUL · 2011 to 2015
$39.5M
PHARMACEUTICAL SCIENCES AND PHARMACOGENOMICST32GM007175 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AHITUV, NADAV, KROETZ, DEANNA L · 1985 to 2021
$7.1M
Role of Factor Acetylation in the Regulation of HIV TranscriptionR01AI083139 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI OTT, MELANIE MARIA · 2009 to 2017
$3.9M
NIAID NIH HHS R01 AI083139NIAID NIH HHS U19 AI096113NIGMS NIH HHS T32 GM007175
6 · The paper itself

Abstract

Persistent viral infections are widespread and represent significant public health burdens. Some viruses endure in a latent state by co-opting the host epigenetic machinery to manipulate viral gene expression. Small molecules targeting epigenetic pathways are now in the clinic for certain cancers and are considered as potential treatment strategies to reverse latency in HIV-infected individuals. In this review, we discuss how drugs interfering with one epigenetic pathway, protein acetylation, perturb latency of three families of pathogenic human viruses-retroviruses, herpesviruses, and papillomaviruses.

Indexed as

Antiviral AgentsDrug Delivery SystemsEpigenesis, GeneticGene Expression RegulationHumansVirus LatencyAntiviral Agents

Identifiers

PMID26845514
PMCPMC5477850
OpenAlexW2278032859

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.